{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:14:45Z","timestamp":1787753685970,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.medcli.2022.09.023","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T07:23:44Z","timestamp":1673076224000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efectividad de anticuerpos monoclonales anti-PRGC en el tratamiento preventivo de la migra\u00f1a: estudio prospectivo de 63 pacientes"],"prefix":"10.1016","volume":"160","author":[{"given":"Ana","family":"Castrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Cerd\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinto","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.09.023_bib0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.09.023_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","article-title":"MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention","volume":"22","author":"Belv\u00eds","year":"2021","journal-title":"J Headache and Pain."},{"key":"10.1016\/j.medcli.2022.09.023_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.medcli.2022.09.023_bib0150","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalagia."},{"key":"10.1016\/j.medcli.2022.09.023_bib0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache."},{"key":"10.1016\/j.medcli.2022.09.023_bib0160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia."},{"key":"10.1016\/j.medcli.2022.09.023_bib0165","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of Erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2022.09.023_bib0170","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","article-title":"Early otcomes of migraine after erenumab discontinuation: data from a real-life setting","volume":"42","author":"De Matteis","year":"2021","journal-title":"Neurol Sci."},{"key":"10.1016\/j.medcli.2022.09.023_bib0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"issue":"10161","key":"10.1016\/j.medcli.2022.09.023_bib0180","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3 b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.09.023_bib0185","unstructured":"Documento de consenso de la Comisi\u00f3n Asesora de Farmacoterapia de Castilla y Le\u00f3n. Galcanezumab y erenumab en la profilaxis de la migra\u00f1a (Versi\u00f3n 2), aprobado el 5\/02\/2020 y publicado el 10\/02\/2020, documento de uso exclusivo para profesionales del Sacyl."},{"key":"10.1016\/j.medcli.2022.09.023_bib0190","unstructured":"Informe de Posicionamiento terap\u00e9utico de erenumab (Aimovig) en la profilaxis de la migra\u00f1a (Agencia espa\u00f1ola de Medicamentos y Productos Sanitarios) [consultado 31 Enero 2022]. https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-erenumab-Aimovig"},{"key":"10.1016\/j.medcli.2022.09.023_bib0195","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.medcli.2022.09.023_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420927119","article-title":"The role of erenumab in the treatment of migraine","volume":"13","author":"Andreou","year":"2020","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.medcli.2022.09.023_bib0205","doi-asserted-by":"crossref","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","article-title":"Erenumab in chronic migraine: patient reported outcomes in a randomized double-blind study","volume":"92","author":"Lipton","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.medcli.2022.09.023_bib0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain."},{"key":"10.1016\/j.medcli.2022.09.023_bib0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicenter descriptive study","volume":"25","author":"Dom\u00ednguez","year":"2018","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.medcli.2022.09.023_bib0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.33588\/rn.7401.2021182","article-title":"Experiencia cl\u00ednica con erenumab durante el primer a\u00f1o de tratamiento","volume":"74","author":"Caso-Gonz\u00e1lez","year":"2022","journal-title":"Rev Neurol."},{"key":"10.1016\/j.medcli.2022.09.023_bib0225","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.medcli.2022.09.023_bib0230","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomided trial of erenumb for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.medcli.2022.09.023_bib0235","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fneur.2019.00678","article-title":"Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxinA-treatment","volume":"10","author":"Schiano di Cola","year":"2019","journal-title":"Front Neurology."},{"key":"10.1016\/j.medcli.2022.09.023_bib0240","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"Headache Pain."},{"key":"10.1016\/j.medcli.2022.09.023_bib0245","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of erenumab: A retrospective cohort sudy","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia."},{"key":"10.1016\/j.medcli.2022.09.023_bib0250","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J Headache Pain."},{"key":"10.1016\/j.medcli.2022.09.023_bib0255","doi-asserted-by":"crossref","first-page":"e2260","DOI":"10.1002\/brb3.2260","article-title":"Predictors of response to erenumab after 12 months of treatment","volume":"11","author":"Baraldi","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.medcli.2022.09.023_bib0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J Headache Pain."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322006212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322006212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:56:12Z","timestamp":1758419772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322006212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0025775322006212"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.09.023","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad de anticuerpos monoclonales anti-PRGC en el tratamiento preventivo de la migra\u00f1a: estudio prospectivo de 63 pacientes","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}